Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11792799 | 0.78 | CYP2A6 (0.39) | POLBNR4A2TYMSALDH1A1HSP90AA1 | |
| SCHEMBL7716192 | 0.77 | SLC2A1 (0.47) | POLBALDH1A1CYP2A6SMN1; SMN2 | |
| SCHEMBL1536340 | 0.77 | L3MBTL1 (0.50) | NR4A2GAAALDH1A1CYP2A6MAPK1 | |
| SCHEMBL30544379 | 0.77 | L3MBTL1 (0.50) | NR4A2GAAALDH1A1CYP2A6MAPK1 | |
| SCHEMBL28810567 | 0.75 | CYP2A6 (0.37) | POLBNR4A2TYMSALDH1A1CYP2A6 | |
| SCHEMBL23591238 | 0.74 | ALDH1A1 (0.44) | POLBGAAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3964092 | 0.72 | CCR1 (0.38) | POLBNR4A2TYMSALDH1A1CYP2A6 | |
| SCHEMBL2987139 | 0.72 | MAOA (0.42) | POLBGAAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15933155 | 0.71 | POLB (0.53) | POLBNR4A2GAACRHR1ALDH1A1 | |
| SCHEMBL16008294 | 0.71 | CYP2A6 (0.39) | ALDH1A1CYP2A6SMN1; SMN2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-4067873-A | TREATMENT OF ARRHYTHMIA, HYPERLIPOIDEMIA, HYPERGLYCEMIA, CORONARY DISEASE | SANDOZ LTD. (CH) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | POLB 821/4885NR4A2 3595/4885GAA 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.